摘要
本文采用竞争性蛋白结合法(CPBA)测定1209例受检者血清25羟基维生素D_3[25(OH)D_3],其中包括0～87岁健康人592例,孕妇与新生儿256例,患者361例(20个病种);并采用放射受体法测定131例受检查者血清1,25二羟基维生素D_3[1,25(OH)_2D_3],其中健康人35例,孕妇与新生儿28例,患者68例。结果表明,血清25(OH)D_3和 1,25(OH)_2D_3水平的变化对钙磷代谢失调及代谢性骨病的诊断、评价治疗和预后有重要参考意义。
Serum concentration of 25-hydroxyvitamin D [25(OH)D_3] in 592 Beijing normal subjects (age: O-87 years), 256 cases maternal and cord blood and 361 patients with 20 different disorders (altogether1209 subjects) were determined by competitive protein binding assay. Decreased serum levels of 25(OH)D_3 compared with normal ware observed in patients with rickets, tetany, pneumonia infantilehepatitis, bone tumor, diabetes and renal disease and increased serum levels of 26 (OH) D_3 was inpatients with Vitamin D overdose and fatty liver. Serum values of 1,25-dihydroxyvitamin D_3 [1,25(OH)_2D_3] were detected by radioreceptor assay in35 Beijing normal subjects, 28 cases of maternal and cord blood and 68 patients (131 in total). Serumvalues of 1,25(OH)_2D_3 was lower than normal in uremic, nephrotic syndrome and osteoporotic patientsand higher than normal in pregnant women. The results show that the variations of serum 25(OH)D_3 and 1,26(OH)_2D_3 are valuble indicatorsfor diagnosis, evaluating treatment and prognosis of metabolic bone disease.
出处
《北京医科大学学报》
CSCD
1991年第2期135-137,共3页
Journal of Peking University(Health Sciences)
关键词
维生素D3
代谢性骨病
Vitamin D_3
Metabolic bone disease
